Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. by Rai, Sharan K et al.
UCSF
UC San Francisco Previously Published Works
Title
Approaches for estimating minimal clinically important differences in systemic lupus 
erythematosus.
Permalink
https://escholarship.org/uc/item/500315nt
Journal
Arthritis research & therapy, 17(1)
ISSN
1478-6354
Authors
Rai, Sharan K
Yazdany, Jinoos
Fortin, Paul R
et al.
Publication Date
2015-06-03
DOI
10.1186/s13075-015-0658-6
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Rai et al. Arthritis Research & Therapy  (2015) 17:143 
DOI 10.1186/s13075-015-0658-6REVIEW Open AccessApproaches for estimating minimal clinically
important differences in systemic lupus
erythematosus
Sharan K Rai1,2, Jinoos Yazdany3, Paul R Fortin4 and J Antonio Aviña-Zubieta1,5*Abstract
A minimal clinically important difference (MCID) is an important concept used to determine whether a medical
intervention improves perceived outcomes in patients. Prior to the introduction of the concept in 1989, studies
focused primarily on statistical significance. As most recent clinical trials in systemic lupus erythematosus (SLE)
have failed to show significant effects, determining a clinically relevant threshold for outcome scores (that is,
the MCID) of existing instruments may be critical for conducting and interpreting meaningful clinical trials as
well as for facilitating the establishment of treatment recommendations for patients. To that effect, methods
to determine the MCID can be divided into two well-defined categories: distribution-based and anchor-based
approaches. Distribution-based approaches are based on statistical characteristics of the obtained samples.
There are various methods within the distribution-based approach, including the standard error of measurement,
the standard deviation, the effect size, the minimal detectable change, the reliable change index, and the standardized
response mean. Anchor-based approaches compare the change in a patient-reported outcome to a second, external
measure of change (that is, one that is more clearly understood, such as a global assessment), which serves as the
anchor. Finally, the Delphi technique can be applied as an adjunct to defining a clinically important difference.
Despite an abundance of methods reported in the literature, little work in MCID estimation has been done in the
context of SLE. As the MCID can help determine the effect of a given therapy on a patient and add meaning
to statistical inferences made in clinical research, we believe there ought to be renewed focus on this area.
Here, we provide an update on the use of MCIDs in clinical research, review some of the work done in this
area in SLE, and propose an agenda for future research.Introduction
A minimal clinically important difference (MCID) is an
important concept used to determine whether a medical
intervention improves perceived outcomes in patients.
Prior to the introduction of the concept in 1989, studies
focused primarily on statistical significance [1]. As clini-
cians, investigators, and policy-makers are becoming in-
creasingly interested in incorporating patients’ attitudes,
priorities, and perspectives on disease in the longitudinal
evaluation of novel intervention strategies, questionnaires
assessing health-related quality of life (HR-QOL) and per-
ceived health status are gaining widespread use. However,* Correspondence: azubieta@arthritisresearch.ca
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unless otherwise stated.despite the abundance of such instruments, their in-
terpretability poses a challenge to investigators. MCID
directly addresses the limitations of examining statis-
tical significance in isolation, particularly the possibility
that studies may find statistical relationships that do not
have clinical importance to patients, clinicians, or policy-
makers.
Systemic lupus erythematosus (SLE) is a chronic, multi-
system autoimmune disease that illustrates some of the
challenges posed by defining and measuring MCIDs. SLE
is a heterogeneous disease with a wide variety of symp-
toms in individual patients and across the population.
Furthermore, SLE is characterized by periods of low
disease activity alternating with periods of higher dis-
ease activity, a pattern that directly impacts the patient’s
quality of life [2]. However, outcome measures that captures is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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array of symptoms and signs have been challenging to
both develop and apply, and limited work has been
done to define MCIDs for existing patient-reported mea-
sures [3]. Although there has been work applying generic
health status instruments in SLE (for example, the Medical
Outcomes Study 36-Item Short Form (SF-36), for which
an improvement of 2.5 points has been defined as the
MCID in SLE [4, 5]), these tools are known to have rela-
tively poor responsiveness in SLE [6, 7]. Thus, there is a
need to bring new focus and methodology to MCID meas-
urement in SLE. Here, we provide an update on the use
of MCIDs in clinical research, review some of the work
done in this area in SLE, and propose an agenda for future
research.Defining a clinically meaningful difference
The MCID has been proposed as the ‘smallest difference
in score in the domain of interest which patients perceive
as beneficial and which would mandate, in the absence of
troublesome side effects and excessive cost, a change in the
patient’s management’ [1]. The MCID therefore constitutes
a threshold for outcome scores (either patient-reported or
physician-measured) over which a patient or physician
would consider a given change in score to be meaningful
and worthwhile, which is critical for conducting clinical
trials in SLE as well as for facilitating the establishment of
treatment recommendations for patients [2, 8].Minimal clinically important difference in the
context of systemic lupus erythematosus
The Belimumab in Subjects With Systemic Lupus Erythema-
tosus (BLISS)-52 [9] and BLISS-76 [10] trials of belimumab
(the first drug approved for SLE in over 50 years) employed
the SLE Responder Index (SRI), the first composite meas-
ure of SLE disease activity that incorporates criteria from
three different validated indices: the Safety of Estrogens in
Lupus Erythematosus - National Assessment-SLE Disease
Activity Index (SELENA-SLEDAI), a Physician Global
Assessment, and the British Isles Lupus Assessment Group
(BILAG) instrument [11]. This composite index provides a
more comprehensive assessment of SLE disease activity
because it uses several instruments simultaneously, thus
leveraging the relative advantages and disadvantages of
various available indices [11]. In addition to the SRI, the
Physical Component Summary (PCS) of the SF-36, a gen-
eric instrument for measurement of HR-QOL that has
been validated for use in SLE clinical trials, was used to as-
sess change in HR-QOL following treatment with beli-
mumab [9, 10]. Results of the trial showed significant
improvement in SF-36 scores across both belimumab
groups (1 and 10 mg/kg) at week 52, which correlated
with an SRI response (as compared with non-responders)[9]. However, as the SF-36 is not a measure of disease ac-
tivity, it was not included in the SRI [12].
Unlike the BLISS trials, many other recent trials - for
example, the Exploratory Phase II/III SLE Evaluation of
Rituximab (EXPLORER) [13], the Lupus Nephritis Assess-
ment with Rituximab (LUNAR) [14], and the abatacept
[15] trials - have all reported non-statistically significant
results. In the case of rituximab, this is especially disap-
pointing in light of several smaller uncontrolled trials that
suggested potential efficacy in SLE [16–19]. Thus, the
manner in which a response is defined holds the potential
to determine whether a clinical trial is deemed a success
or a failure [20]. This has been demonstrated in the con-
text of lupus nephritis, in which Wofsy and colleagues
[20] aimed to determine which response criteria are most
sensitive to differences among treatment groups.
Thus, as several clinical trials in SLE to date have failed
to show significant effects, defining the MCID of existing
instruments (as well as composite indices, such as the
SRI) may be critical for the conduct of interpretable and
meaningful clinical trials in SLE, as it will help determine
the effect of a given therapy as well as assist with appro-
priate design of clinical trials by informing the estimation
of effect size, thus facilitating sample size calculation.
Perspectives on the minimal clinically important
difference
The MCID can be defined from the perspective of the pa-
tient (or the patient’s proxy, such as a caretaker or part-
ner), health-care professionals, or researchers [21, 22]. For
example, the patient may consider a meaningful difference
to be one that results in a reduction of symptoms or an
improvement in function, thus allowing him or her to per-
form an essential task or to perform tasks more efficiently
(for example, with less pain), but this would not neces-
sarily take into account an intervention’s impact on sur-
vival or damage [21]. Conversely, a physician may define a
meaningful difference to be a change in treatment or dis-
ease prognosis [23]. Additionally, the MCID can be fur-
ther defined from the perspective of society, which would
define a meaningful change as one that allows a patient
to return to employment, or of the payers (for example,
an insurance company), who would define a meaningful
change as one that produces a claim closure [22]. Given
the diversity of available perspectives, definitions of the
MCID may (and likely will) be discordant.
The MCID may also be defined at either the individual
or group level (and will vary accordingly). Inferences made
at the group level can inform comparisons between differ-
ent treatments or decisions regarding public policy; con-
versely, inferences made at the individual level can inform
individual clinical treatment decisions [23]. Furthermore,
when considering the magnitude necessary for a change to
be considered important, larger changes may be required
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may be interpreted as clinically important when considered
at the group level [23, 24].
Health-related quality of life
The discordance between physician and patient perspec-
tives raises the question of who ought to decide what
constitutes a clinically meaningful change. Patients’ per-
ceptions of clinically worthwhile changes are influenced by
their health status at baseline as well as their expectations,
needs, and goals [21]. Conversely, the clinician’s judgment
draws upon previous knowledge and experiences, consider-
ation of things that could be treated, and an understanding
of physiologic findings that may not be symptomatic to the
patient [21]. Thus, it has been suggested that for measures
of physical function and quality of life, responsiveness
should be based on the subject’s perception of meaningful
change but that for measures of impairment or disease ac-
tivity, the physician may provide the best judgment [21].
To that effect, various international and multidisciplinary
bodies (for example, the Outcome Measures in Rheuma-
tology group) have developed a core set of outcome do-
mains for rheumatic diseases (as had originally been done
for rheumatoid arthritis clinical trials) [25, 26]. Specifically,
they have recommended that the following constitute a
core set of domains for SLE clinical trials: disease activity,
HR-QOL, adverse events, and cumulative organ damage
[25, 26]. Whether some of these domains should be com-
bined into a composite index (as in the SRI) or evaluated
individually warrants further investigation.
The importance of including HR-QOL as a core domain
cannot be overstated, as it would incorporate the patient’s
perspective of the impact of therapy on various physical, so-
cial, and psychological aspects of their health. For example,
although a new therapy might show a clinically relevant
improvement in disease activity as measured by available
indices, this improvement may be contrasted by a clinically
meaningful worsening in the patient’s HR-QOL (for ex-
ample, due to side effects). The converse may also be true:
subjective improvements (for example, fatigue, an ex-
tremely disabling symptom among patients with SLE) may
not be captured by a disease activity index. In this case, cap-
turing clinically meaningful changes in fatigue level could
provide great insight into the development and acceptance
of new therapeutic agents. Indeed, a trial of the efficacy of
abatacept reported that although the study’s primary and
secondary endpoints were not met, treatment effects were
seen in certain exploratory patient-reported measures, such
as in the SF-36, problems with sleep, and fatigue [15].
Methods to determine the minimal clinically
important difference
There are various methods to calculate the MCID and each
has relative advantages and disadvantages. An extensivereview of available methods was published by Wells and
colleagues [27], who classified them into nine different ap-
proaches. Another review proposed three distinct categories
of approaches for defining the MCID: distribution-based
(using statistical descriptions of the population), opinion-
based (relying upon experts), and predictive/data-driven
(using sequential hypothesis formation and testing) [28].
Overall, regardless of the larger framework employed,
methods to determine MCIDs can be divided into two
well-defined categories: distribution-based and anchor-
based approaches [29]. However, despite this dichotomous
classification, distribution-based methods confer the most
use when they are applied together with a meaningful ex-
ternal anchor [30].
Anchor-based methods
Anchor-based approaches compare the change in a patient-
reported outcome with a second, external measure of
change, which serves as the anchor [29]. Given the large
selection of external criteria, this approach can be quite
varied [31]. The anchor can be either an objective (for ex-
ample, medication use or health-care utilization) or sub-
jective (for example, patient self-report of improvement or
worsening) measure; however, given the limited availabil-
ity of acceptable objective assessments, few studies have
employed an objective anchor [32, 33]. Instead, anchor-
based methods generally rely on the use of a subjective
assessment (most commonly a global assessment) [32].
Importantly, these anchor-based methods have the advan-
tage of linking the change in a given score to the patient’s
perspective (which is captured by the anchor) [23].
According to a comprehensive review by Copay and col-
leagues [32], four variations of the anchor-based approach
can be described: (a) the ‘within-patients’ score change, (b)
the ‘between-patients’ score change, (c) the sensitivity- and
specificity-based approach, and (d) the social comparison
approach. Another extensive review, by Crosby and col-
leagues [23], summarized various anchor-based methods
for determining individual change according to cross-
sectional versus longitudinal methods, with longitudinal
methods being more linked with change and thus confer-
ring a benefit over cross-sectional methods. To that effect,
employing a longitudinal approach is of particular benefit
in SLE, which is characterized by fluctuating status due to
flares and remissions.
In addition to determining the responsiveness of the SLE
Activity Questionnaire (SLAQ) by using the standard-
ized response mean (SRM), the aforementioned study by
Yazdany and colleagues [34] further examined the respon-
siveness of the SLAQ among a large observational cohort
of SLE patients by employing clinically relevant and vali-
dated patient assessments of disease activity and health
status (for example, the SF-36 Physical Functioning
subscale) as the anchors. SLAQ scores were found to
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(that is, the anchors), with the exception of the Short-
Form 12 PCS [34].
Limitations of the anchor-based methods
First, the application of different anchors or anchor types
may produce different values of the MCID [32], although
this is not unlike the distribution-based methods in which
different statistical approaches will also produce a variety
of MCID values. Additional limitations include a potential
discordance of defined MCID values based on whether
data collection of the anchor was prospective versus retro-
spective [35], the possibility that the MCID as determined
by anchor-based methods falls within the instrument’s
random variation [23], and the susceptibility of some rat-
ings to recall bias [23] (although perhaps this may be alle-
viated by considering the necessity or wish for change in
medication at a given time point, rather than the change
over time, which warrants further research).
Distribution-based methods
Distribution-based interpretations are based on statistical
characteristics of the obtained samples [29]. There are
various methods within the distribution-based approach,
including the standard error of measurement (SEM), the
standard deviation, the effect size, the minimal detectable
change, the reliable change index (RCI), and the SRM.
Standard error of measurement
The SEM is defined as the variation in patient-reported
outcome scores attributed to instrument unreliability, in
which a change smaller than the calculated SEM is likely
due to measurement error rather than a true change [32].
Thus, the SEM is considered to be a characteristic of the
measure, not the sample [36]. To define the MCID,
threshold values of 1 SEM, 1.96 SEM, and 2.77 SEM have
been suggested [36–38]. To illustrate, the MCID can be
defined by using the SEM of changes in disease activity
scores of SLE patients who have stable disease (that is, pa-
tients rated as having no change in disease between con-
secutive visits) [39]. This was done in a recent study that
determined the MCID of validated measures of SLE dis-
ease activity in childhood-onset SLE [39]. The MCID was
based on both the 1-SEM criterion (which makes the as-
sumption that meaningful improvement or worsening has
occurred if the change is plus or minus 1 SEM, respect-
ively) and a more strict criterion (that is, ± 1.645 SEM)
[39]. A tighter confidence interval resulted in a more ac-
curate detection of patients with stable disease versus
those who experienced clinically important change [39].
Standard deviation
Another measure of variability is the standard deviation
[32], defined as the variation among a group of scores,for which 0.5 standard deviations has been suggested to
correspond to the MCID in a number of studies [40].
An example of this method is provided in a study by
Katz and colleagues [41], in which changes in valued life
activity scores from baseline to the end of the follow-up
were defined as clinically meaningful on the basis of the
criterion of at least 0.5 standard deviations.Effect size
The effect size is a standardized measure of change ob-
tained by dividing the difference in scores from baseline
to post-treatment by the standard deviation of baseline
scores [32]. For interpreting effect sizes, Cohen [42] has
proposed the following benchmarks: 0.20, 0.50, and 0.80,
indicating small, moderate, and large effects, respect-
ively. Practically speaking, the effect size should be small
in patients reporting no change and large in patients
reporting a great improvement [43]. In a study by Fortin
and colleagues [44], the effect size was employed to de-
termine the responsiveness of two lupus activity mea-
sures: the revised Systemic Lupus Activity Measure
(SLAM-R) and the SLEDAI. Based on this methodology,
the SLAM-R performed better than or the same as the
SLEDAI for both clinical improvement and worsening.
With regard to no change, the two measures performed
equally well.Minimal detectable change
A measure of variability associated with the SEM is the
minimal detectable change (MDC), which is the smal-
lest detectable change that can be considered above the
measurement error with a given level of confidence (usu-
ally 95 % confidence) [32]. Although this method has
not been used in SLE research to date, we provide an
example from a study of a comprehensive rehabilitation
intervention among patients with osteoarthritis by using
the Western Ontario and McMaster Universities Arthritis
Index (WOMAC) and the SF-36 to estimate the MDC
and the MCID for improvement [45]. In the WOMAC
sections, the MDC ranged from 0.75 (global) to 0.96 (stiff-
ness), whereas in the SF-36 the MDC ranged from 2.8
(PCS) to 7.6 (physical function) [45]. The correspond-
ing values for MCID in the WOMAC sections ranged
from 0.51 to 1.33 points (on a scale of 0 to 10) and
in the SF-36 the values ranged from 2.0 to 7.8 points
(on a scale of 0 to 100), respectively [45]. These find-
ings have implications for the design of meaningful
clinical trials, as sections that showed moderate re-
sponsiveness (for example, the SF-36 bodily pain) re-
quire a relatively lower sample size as compared with
sections that demonstrated lower responsiveness (for
example, the SF-36 physical function), which require
larger sample sizes.
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The RCI is a statistic that assesses the magnitude of change
necessary for a given self-report measure to be considered
statistically reliable. It is calculated by dividing the individ-
ual patient change score by the square root of the SEM
[32]. The RCI is considered to confer a true change when
it is more than 1.96 (95 % confidence) (that is, the z-score
corresponding to the desired level of significance) [32]. Al-
though we are not aware of the application of this method
in SLE research to date, it has been used to determine the
clinical significance of the SF-36 [46]. Specifically, the
RCIs were calculated to be 7.47 and 9.70 (reported in
T-score units, the standard metric for scoring and inter-
preting the SF-36), corresponding to the PCS and Mental
Component Summary, respectively (calculated at the 0.05
level of significance).
Standardized response mean
The SRM is similar to the effect size, except the change
in score is divided by the standard deviation of that change
[23]. Similar benchmarks have been proposed to guide the
interpretation of the SRM [47–49]. In the aforementioned
study by Fortin and colleagues [44], the SRM was also
employed to determine the responsiveness of both the
SLAM-R and the SLEDAI. The same pattern was noted
for the comparison of the two measures as was reported
for the effect size approach [44]. Furthermore, a study by
Yazdany and colleagues [34] ascertained the responsive-
ness of the SLAQ by calculating the SRM and found that
the SLAQ demonstrated a small to moderate degree of re-
sponsiveness for patients reporting a perceived change in
disease status. Although the overall SRM was found to be
0.12 (that is, minimally responsive [42]), after stratification
by patient changes in the patient global assessment of dis-
ease activity the SRMs were found to be 0.66 and −0.37,
corresponding to clinical deterioration and improvement,
respectively. Furthermore, the SRM of no change was
found to be 0.10. These values are similar to those ob-
tained for other commonly employed disease activity indi-
ces among patients with SLE [50].
Limitations of the distribution-based methods
First, it must be noted that the application of the various
distribution-based approaches described above will result
in different definitions of the MCID, which contradicts
the intended aim of defining a specific threshold [32].
Most importantly, distribution-based methods are limited
by their ability to define only a minimal value below which
a change in outcome score for a given measure may be
due to measurement error [33], which does not provide
information on clinical importance. Thus, these methods
largely ignore the core of the MCID, which is to define the
clinical importance of a given change in outcome scores
separate from their statistical significance [32].Delphi method
The Delphi technique is a well-used method (opinion-
based) for the development of a formal consensus [27, 51]
and can serve as a useful adjunct to finalize MCID values
following application of either the distribution- or anchor-
based methods. The Delphi method involves the presenta-
tion of a questionnaire or interview to a panel of individuals
in a specific field for the purpose of obtaining a consensus
[52]. Participants are initially sent a questionnaire and
asked to record their views; then, participants revise these
responses after viewing the responses of co-participants,
typically by using a Likert scale [51]. These responses are
collected by the organizers and re-distributed to partici-
pating individuals as a summary of the group’s judgment,
as are the individuals’ responses [51]. Despite substantial
divergence of individual opinions in the first round of a
Delphi investigation, there is a tendency for convergence
of opinions toward a consensus after several iterations of
this multi-step process (often repeated several times) [52].
This method has been increasingly used to develop classifi-
cations as well as response criteria for rheumatic diseases.
Recently, Brunner and colleagues [53] applied the Delphi
survey method to achieve consensus on a definition of
global flares in juvenile SLE and to derive candidate cri-
teria to measure juvenile SLE flares. Outside the context
of SLE, a study determining the MCID in activity limita-
tion, fatigue, and sleep quality among rheumatoid arthritis
patients initially used an internal-anchor approach, and
after the preliminary MCID values were determined, the
Delphi exercise was applied to reach a consensus on the
final MCID values [54].
Recommendations and future research agenda
As most clinical trials in SLE to date have failed to show
significant effects, determining the MCID of the instru-
ments used to measure response may be critical for the
conduct and interpretability of meaningful future clinical
trials. However, little work in MCID estimation has been
done in the context of SLE. Given that the MCID can
help determine the effect of a given therapy on a patient
and add meaning to statistical inferences made in clin-
ical research, we believe there ought to be renewed focus
on this area.
Specifically, we propose the following research agenda
in the context of MCID.
1. Explicitly involving patients in defining MCIDs.
Assessment of subjective yet equally important and
disabling disease characteristics (for example, fatigue
and physical functioning) holds the potential to
incorporate the patient’s perspective in a standardized
way, thus facilitating the development of new
therapies while making significant contributions that
are valued by those who have the disease.
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disease to increase responsiveness. Given the
heterogeneity of SLE, we suspect that research will
proceed more efficiently if some work attempts to
evaluate patients with similar types of SLE (for
example, individuals with a flare of lupus nephritis
or with similar disease activity - either by organ
involvement or global disease - level at baseline).
3. Incorporating health assessment instruments in the
MCID as part of the overall assessment of response.
General health assessment questionnaires, such as
those that evaluate HR-QOL or use state-of-the-art
methods to define a broad array of relevant
symptoms (for example, the Patient Reported
Outcome Measurement System, also known as
PROMIS, an accessible ‘item bank’ to measure
health concepts applicable to a variety of chronic
conditions [55]) will likely be a fruitful area for
future research in MCID among patients with
SLE.
4. Assessment of individual organ involvement
independent from overall disease activity. In addition
to the assessment of overall disease activity, of
particular importance is the assessment of disease
outcome in terms of overall organ involvement, as
SLE represents a systemic disease in which disease
activity can improve in some organ systems while it
worsens in others [8]. This concept is captured in
the BILAG index but would benefit from adding the
MCID (either alone or as part of the SRI) to further
improve responsiveness, although the BILAG may
have to be reweighted accordingly.
5. Development of a grading response using the MCID.
Research is needed into the potential application of
grading response (for example, small, moderate, or
large response) in SLE using the MCID (rather than
a binary concept), which may be an important
discriminatory parameter to measure responsiveness
in SLE.
6. Scoring using multiple instruments simultaneously.
Finally, to appropriately account for these various
domains in a disease as heterogeneous as SLE, it is
imperative that we continue to develop a way to
score multiple instruments simultaneously. To that
end, further research is warranted to better
understand the MCID of the various instruments
available.
7. Determine whether the MCID is dependent upon
the direction of the change in score (that is, clinical
improvement versus worsening). As the MCID of a
given self-report measure may vary depending on
whether the reported change in score is positive or
negative, this ought to be considered when scoring
these instruments [56].In summary, as new therapies are urgently required to
treat this devastating and debilitating disease, we cannot
afford to wait another 50 years before adding another ther-
apy to the armamentarium for SLE management. Thus, to
facilitate further development of new therapeutic agents
for SLE, it is critical that funding agencies, researchers, pa-
tient organizations, and industry sponsors work collabora-
tively to close existing knowledge gaps on appropriate
measurement of response in SLE.
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